Giulumian A D, Pollock D M, Clarke N, Fuchs L C
Department of Pharmacology and Toxicology, Vascular Biology Center, Medical College of Georgia, Augusta, Georgia 30912, USA.
Am J Physiol. 1998 Jun;274(6):R1613-8. doi: 10.1152/ajpregu.1998.274.6.R1613.
Endothelin-1 (ET-1) is thought to play an important role in the development of deoxycorticosterone acetate (DOCA)-salt hypertension. Because hypertension is associated with an increased incidence of coronary artery disease, this study was designed to determine if coronary vascular contraction to ET-1 is altered in DOCA-salt hypertensive rats and to determine the effect of chronic treatment of DOCA-salt rats with the selective ETA receptor antagonist A-127722. Male Sprague-Dawley rats were divided into four groups: DOCA, Placebo, DOCA + A-127722, and Placebo + A-127722. A-127722 was administered in drinking water at a concentration of 8 mg/100 ml. After 3 wk, mean arterial pressure (MAP) was significantly enhanced in DOCA-salt compared with Placebo rats. A-127722 significantly inhibited the increase in MAP. Contraction to ET-1 (10(-11) to 3 x 10(-8) M) was measured in isolated coronary and mesenteric small arteries (200-300 micron, intraluminal diameter) maintained at a constant intraluminal pressure of 40 mmHg and was significantly impaired in vessels from DOCA-salt compared with Placebo rats. Dose-dependent contractions to KCl were also inhibited in coronary, but only minimally impaired in mesenteric, arteries of DOCA-salt rats. Inhibition of nitric oxide synthase activity did not restore contraction to ET-1 in coronary small arteries. However contractions to ET-1 were enhanced in mesenteric small arteries. Chronic treatment with A-127722 significantly restored contraction to ET-1 in coronary, but not in mesenteric, arteries of DOCA-salt rats. Because ETA receptor blockade impairs the development of hypertension and improves coronary vascular reactivity, these data indicate that ET-1 plays an important role in coronary vascular dysfunction associated with DOCA-salt hypertension.
内皮素-1(ET-1)被认为在醋酸脱氧皮质酮(DOCA)-盐性高血压的发展中起重要作用。由于高血压与冠状动脉疾病发病率增加相关,本研究旨在确定DOCA-盐性高血压大鼠对ET-1的冠状动脉收缩是否改变,并确定用选择性ETA受体拮抗剂A-127722长期治疗DOCA-盐性大鼠的效果。雄性Sprague-Dawley大鼠分为四组:DOCA组、安慰剂组、DOCA + A-127722组和安慰剂 + A-127722组。A-127722以8 mg/100 ml的浓度加入饮用水中给药。3周后,与安慰剂组大鼠相比,DOCA-盐组大鼠的平均动脉压(MAP)显著升高。A-127722显著抑制了MAP的升高。在保持管腔内压力恒定为40 mmHg的离体冠状动脉和肠系膜小动脉(管腔内直径200 - 300微米)中测量对ET-1(10^(-11)至3×10^(-8) M)的收缩反应,与安慰剂组大鼠相比,DOCA-盐组大鼠血管中的收缩反应明显受损。DOCA-盐组大鼠冠状动脉中对氯化钾的剂量依赖性收缩也受到抑制,但肠系膜动脉中仅轻微受损。抑制一氧化氮合酶活性并未恢复冠状动脉小动脉对ET-1的收缩。然而,肠系膜小动脉中对ET-1的收缩增强。用A-127722长期治疗可显著恢复DOCA-盐组大鼠冠状动脉中对ET-1的收缩,但不能恢复肠系膜动脉中的收缩。由于ETA受体阻断会损害高血压的发展并改善冠状动脉血管反应性,这些数据表明ET-1在与DOCA-盐性高血压相关的冠状动脉血管功能障碍中起重要作用。